Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 20 Jan 2025
European Commission expands Jemperli (dostarlimab) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer
20 January 2025 - Expanded approval includes MMRp/MSS tumours, which represent approximately 75% of endometrial cancer cases. ...
Posted by Michael Wonder on 20 Jan 2025
BIO statement on new list of medicines targeted for Government price setting
17 January 2025 - The Biotechnology Innovation Organization (BIO) today released the following statement after the Biden administration released a ...
Posted by Michael Wonder on 20 Jan 2025
Australians benefit from freeze to maximum cost of PBS medicines
20 January 2025 - The Australian Government has launched an advertising campaign to raise awareness about a freeze on the maximum ...
Posted by Michael Wonder on 20 Jan 2025
Handok's AML treatment Vyxeos receives insurance coverage in Korea
2 December 2024 - Handok said Monday that its acute myeloid leukaemia treatment, Vyxeos liposomal injection (cytosine arabinoside and daunorubicin ...
Posted by Michael Wonder on 19 Jan 2025
Protection against RSV for mums and bubs with free vaccine available from 3 February
19 January 2025 - From 3 February 2025, Australian mums and their newborn babies will have free access to the best ...
Posted by Michael Wonder on 19 Jan 2025
Human medicines in 2024
16 January 2025 - In 2024, EMA recommended 114 medicines for marketing authorisation. ...
Posted by Michael Wonder on 19 Jan 2025
Junshi Biosciences announces toripalimab’s approval in Australia
17 January 2025 - Shanghai Junshi Biosciences announced that toripalimab, the anti-PD-1 monoclonal antibody self-developed by the company, has obtained the ...
Posted by Michael Wonder on 19 Jan 2025
Long wait for cancer drug approvals causing 'great anguish' among patients, doctors
18 January 2025 - Potentially life-saving treatments delayed by bureaucracy, doctors say. ...
Posted by Michael Wonder on 19 Jan 2025
New EU rules for health technology assessments become effective
10 January 2025 - Enhanced EU collaboration to allow faster and wider access to innovative health technologies. ...
Posted by Michael Wonder on 19 Jan 2025
Ozempic among the next drugs up for Medicare price negotiations
17 January 2025 - List of drugs account for $41 billion in annual Medicare spending, Biden administration says. ...
Posted by Michael Wonder on 19 Jan 2025
Aprocitentan approved to treat adults with hypertension whose blood pressure cannot be controlled by other medications
17 January 2025 - The MHRA has approved the medicine aprocitentan (Jeraygo) to treat hypertension in adults whose blood pressure cannot ...
Posted by Michael Wonder on 19 Jan 2025
US FDA approves FoundationOne CDx as a companion diagnostic for Ojemda (tovorafenib) to treat the most common form of childhood brain tumour in paediatric patients
17 January 2025 - The approval supports the identification of therapeutic options for patients with relapsed or refractory BRAF altered paediatric ...
Posted by Michael Wonder on 18 Jan 2025
Illuccix receives European approval
17 January 2025 - Telix today announces that it has received a positive decision on the marketing authorisation application for ...
Posted by Michael Wonder on 18 Jan 2025
Arrowhead Pharmaceuticals announces acceptance of new drug application by US FDA of plozasiran for the treatment of familial chylomicronaemia syndrome
17 January 2025 - The new drug application is based on positive results from the Phase 3 PALISADE study. ...
Posted by Michael Wonder on 18 Jan 2025
Health Canada approves Otsuka and Lundbeck's Abilify Asimtufii (aripiprazole), the first and only, once every two months, long-acting injectable treatment for schizophrenia and for maintenance monotherapy of bipolar I disorder in adults
17 January 2025 - Otsuka Pharmaceutical Canada and Lundbeck Canada announce that Health Canada has issued a Notice of Compliance ...